摘要
目的探讨肺复康合剂联合地塞米松对大鼠肺纤维化的抑制作用。方法 40只SD雄性大鼠随机分为正常组、模型组(博来霉素造模)、地塞米松组(地塞米松)、肺复康组(肺复康合剂)、肺复康+地塞米松组(肺复康合剂+地塞米松),除正常组外,其余组均复制肺纤维化动物模型。于给药后第28天,各组体重变化、肺系数变化情况,血清透明质酸(HA)、层粘连蛋白(LN)、IV型胶原(CIV)水平的变化情况,进行观察和比较。结果与正常组相比,模型组体重明显降低,肺系数、血清LN、HA、CIV水平均明显升高,P<0.05;与模型组相比,地塞米松组、肺复康组、肺复康+地塞米松组体重明显增加,肺系数、血清LN、HA、CIV水平均显著降低,P<0.05;与地塞米松组组相比,肺复康+地塞米松组各项指标变化更为明显,P<0.05。结论肺复康合剂联合地塞米松治疗通过抑制成纤维细胞增殖,抑制大鼠肺纤维化。
Objective To study the inhibition role of Feifukang mistura combined with dexamethasone on rat pulmonic fibrosis.Methods The 40 male SD rats were randomized into the control group,model group(blemycin model,BLM),dexamethasone group(dexamethasone,DEX),Feifukang group(Feifukang mistura),and Feifukang+ DEX group(Feifukang mistura+DEX).Except for the control group,the rest groups were established the animal model of pulmonary fibrosis.After 28-day postdrug administration,the changes of weight and lung coefficient,serum hyaluronic acid(HA),laminin(LN),type IV collagen(CIV)in the all groups were observed and compared.Results compared with the control group,the weight was significantly reduced,the lung coefficient,HA,LN,CIV levels were obviously increased in the model group,P〈0.05;compared with the model group,the weight was significantly increased,the lung coefficient,HA,LN,CIV levels were obviously decreased in the DEX group,Feifukang group and Feifukang + DEX group,P〈0.05;compared with the DEX group,the all paremeters changes in the Feifukang + DEX group were more significant,P〈0.05.Conclusion The treatment of Feifukang mistura combined with dexamethasone can inhibit the rat pulmonic fibrosis by inhibition of fibrosis cell proliferation.
出处
《滨州医学院学报》
2016年第1期1-4,共4页
Journal of Binzhou Medical University
基金
国家自然科学基金(81273957)
滨州医学院科技重点计划(BY2012KJZD10)
关键词
肺复康合剂
地塞米松
肺纤维化
增殖
feifukang mistura
DEX
pulmonic fibrosis
proliferation